Maurizio Volterrani
Maurizio Volterrani is an expert in Cardiology at IRCCS San Raffaele Pisana (Italy). As of October 2026, ScienceLeadR ranks Maurizio Volterrani in the top 1% of experts worldwide for Heart Failure. Maurizio Volterrani has authored 387 publications, the most recent in 2026, and is an investigator in 24 clinical trials, 4 of them ongoing. SLR score: 1,548 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Hematology - Biochemistry - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
• Full Professor in Exercise and Clinical Science and Quality of Life at the San Raffaele Open University in Rome.
• Director of the Cardio-Pulmonary Department at IRCCS San Raffaele in Rome.
I obtained My MD degree and cardiology specialisation at the University of Brescia (1990) while my PhD was obtained at the University of Cagliari (2011).
My main research interests include heart failure, exercise training in cardiac rehabilitation, telemedicine, hyperkalaemia and kidney failure and, recently, artificial intelligence. I am and have been National Lead as well as Principal Investigator of multiple international clinical trials mainly related to heart failure and his other field of interest.
In the 2024-2026 turn I was Member and Fellow of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and chairperson of the HFA ICARe Committee (Improving Care through Accreditation and Recognition in Heart Failure (ICARe-HF)). I was also chair of the HFA Digital Health and Tele-monitoring Committee as well as a non-voting member of the ESC working group on e-Cardiology.
In 2023 I took part in the ESC Guideline Task Forces for the management of arterial hypertension while in 2022 I was part of the ESC Task-force for the Guidelines for the management of patients with ventricular arrhythmia and prevention of sudden death.
I am President of the Italian Society for Heart Failure (ITAHFA), member of the Italian Ministry of Health Network for IRCCS Cardiology Research Hospitals and expert in the Scientific Advisor Group for the European Medicines Agency.
Finally, from 2022- to 2025 I was Editor in Chief of the Monaldi Archive for Chest Diseases, and curretly am Associated Editor of the European Journal of Heart Failure, ESC Heart Failure, Deputy Editor-in-Chief of the Global Cardiology, Member of the Editorial Board of the Cardiac Failure Review, Reviewer for the Journal of the American College of Cardiology, Nature Medicine, Cocharne, European Heart Journal, European Journal of Heart Failure, Journal of Cachexia, Sarcopenia and Muscle, European Journal of Preventive Cardiology, Reviewer Editor for Frontiers in Physiology and Frontiers in Sports and Active Living. My current H-Index is 60 (Scopus) and has authored over 290 articles.
H- Index : 60 (2026 - Scopus)
Orcid: 0000-0002-2624-9213
Organizations
Career arc: 2009 - 2026
Number : 387
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 24
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| HF POLARIS A research study to look at how well NNC0487 0111 works compared to placebo in people with heart failure and obesity 2025-523717-29-00 — mortality, safety, heart failure, heart, heart failure, diastolic, obesity, morbidity, research | Phase 3 | Recruiting | 2026 |
| Drug Management in Heart Failure NCT06915584 — registries, heart failure, pharmaceutical preparations, heart, therapeutics | N/A | Recruiting | 2024 |
| A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non Obstructive Hypertrophic Cardiomyopathy (nHCM) NCT06081894 — safety, multiple chronic conditions, tablets, cardiomyopathy, hypertrophic, cardiomyopathies | Phase 3 | Active not recruiting | 2023 |
| Italian Digital Primary Cardiovascular Prevention Study NCT05339841 — diabetes mellitus, hypertension, life style, algorithms, mobile applications, risk factors, primary prevention, empowerment, hypercholesterolemia, digital health | N/A | Active not recruiting | 2022 |
LeadR Networks
Main global connection map